The project to investigate mTOR inhibitor-induced immune modulation in subjects with renal cell cancer.
Not Applicable
- Conditions
- advanced renal cell carcinoma
- Registration Number
- JPRN-UMIN000009662
- Lead Sponsor
- Departmentof Urology, Faculty of Life Sciences, Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with known hypersensitivity to temsirolimus or its metabolites (including sirolimus). 2.Female patients of childbearing potential (including male patients of planning to childbear ) and becoming pregnant. 3.Patients treated with m-TOR inhibitor or performed prior immunotherapy within 6 months. 4.Patients treated with systemic steroidal therapy or immunosuppressive drug. 5.Patients with brain metastasis. 6.Patients with active double cancers. 7.Patients with active infectious disease. 8.In addition, patients whom a doctor in judge unsuitable as a candidate patients of an examination.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method